Cardiovascular Phase 3 Readout Calendar
Industry-sponsored cardiovascular trials with primary completion in the next 12 months or last 12 months.
Data last updated September 20, 2026 · source: ClinicalTrials.gov
All areas OncologyImmunologyMetabolicCNSCardiovascularRare DiseaseRespiratoryInfectious DiseaseOphthalmologyMusculoskeletalDermatologyRenal
20
Next 6 months
30
Next 12 months
8
Results posted
147
Phase 3 Cardiovascular
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 cardiovascular trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
What cardiovascular trials are reading out soon?
The "upcoming" section shows industry-sponsored Phase 3 cardiovascular trials with primary completion ahead, soonest first, each graded by how credible that date is.
Which cardiovascular trials have already read out?
The "recently read out" section shows Phase 3 cardiovascular trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.
How are these readout dates sourced?
Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.
Where can I see readouts for other therapeutic areas?
The full cross-area calendar is on the main readout calendar; this page is the Cardiovascular slice of it.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Cardiovascular landscape →
Recently read out & awaiting topline — Cardiovascular
· 15Phase 3 cardiovascular trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Alcon Research | Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction | Ocular Hypertension +1 | Completed | Q2 2026 2026-04-06 | Completed · awaiting
Updated 5mo ago
| NCT07082816 |
| Insmed Incorporated | An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Pulmonary Hypertension +1 | Completed | Q2 2026 2026-04-01 | Completed · awaiting
Updated 5mo ago
| NCT05649722 |
| Janssen Research & Development, LLC | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome Asset: Milvexian | Acute Coronary Syndrome | Completed | Q1 2026 2026-02-06 | Completed · awaiting
Updated 5mo ago
| NCT05754957 |
| Daewoong Pharmaceutical Co. LTD. | A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension Asset: DWC202405 | Essential Hypertension | Completed | Q1 2026 2026-02-05 | Completed · awaiting
Updated 6mo ago
| NCT06671392 |
| Bristol-Myers Squibb | A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM Asset: mavacamten | Hypertrophic Cardiomyopathy +2 | Completed | Q1 2026 2026-01-16 | Completed · awaiting
Updated 7mo ago
| NCT03723655 |
| United Therapeutics | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients Asset: Ralinepag | PAH +10 | Completed | Q4 2025 2025-12-31 | Completed · awaiting
Updated 5mo ago
| NCT03626688 |
| Mineralys Therapeutics Inc. | Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension Asset: Lorundrostat | Hypertension | Active Not Recruiting | Q4 2025 2025-12-30 | Completed · awaiting
Updated 7mo ago
| NCT05968430 |
| GB002, Inc. | Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) Asset: Placebo | Pulmonary Arterial Hypertension | Completed | Q4 2025 2025-11-27 | Completed · awaiting
Updated 5mo ago
| NCT05934526 |
| Bristol-Myers Squibb | A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy Asset: Mavacamten | Cardiomyopathy, Hypertrophic | Active Not Recruiting | Q4 2025 2025-11-25 | Completed · awaiting
Updated 9mo ago
| NCT06253221 |
| AstraZeneca | A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Asset: Baxdrostat | Uncontrolled Hypertension +1 | Completed | Q4 2025 2025-11-24 | Completed · awaiting
Updated 5mo ago
| NCT06344104 |
| Boryung Pharmaceutical Co., Ltd | A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C Asset: BR1018A | Essential Hypertension +1 | Completed | Q4 2025 2025-11-11 | Completed · awaiting
Updated 10mo ago
| NCT06165250 |
| Bayer | A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke Asset: Asundexian (BAY2433334) | Prevention of Ischemic Stroke +2 | Completed | Q4 2025 2025-10-23 | Completed · awaiting
Updated 10mo ago
| NCT05686070 |
| Corxel Pharmaceuticals | An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM Asset: Aficamten | Obstructive Hypertrophic Cardiomyopathy | Completed | Q4 2025 2025-10-20 | Completed · awaiting
Updated 8mo ago
| NCT06116968 |
| Actelion | Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Asset: Macitentan 10 mg | Pulmonary Arterial Hypertension | Active Not Recruiting | Q4 2025 2025-10-07 | Completed · awaiting
Updated 5mo ago
| NCT04273945 |
| Daewoong Pharmaceutical Co. LTD. | Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension Asset: DWC202404, DWC202314 | Hypertension +1 | Completed | Q4 2025 2025-10-02 | Completed · awaiting
Updated 7mo ago
| NCT06682000 |
Upcoming cardiovascular readouts — next 12 months
· 30Industry Phase 3 cardiovascular trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Pharmazz, Inc. | Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke Asset: Drug: Normal Saline | Acute Ischemic Stroke +1 | Recruiting | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 9mo ago
| NCT05691244 |
| Shandong Suncadia Medicine Co., Ltd. | A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy Asset: HRS-1893 Tablets | Obstructive Hypertrophic Cardiomyopathy | Active Not Recruiting | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 13mo ago
| NCT07021976 |
| Novo Nordisk A/S | A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation Asset: Ziltivekimab | Heart Failure +1 | Active Not Recruiting | Q4 2026 2026-10-01 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06200207 |
| Novartis Pharmaceuticals | Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events Asset: Inclisiran sodium 300 mg | Coronary Artery Disease | Active Not Recruiting | Q4 2026 2026-10-26 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05360446 |
| Janssen Research & Development, LLC | A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation Asset: Milvexian | Atrial Fibrillation | Active Not Recruiting | Q4 2026 2026-10-31 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05757869 |
Unlock 25 more cardiovascular readouts · plus filters on the full calendar
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.